<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647281</url>
  </required_header>
  <id_info>
    <org_study_id>202007</org_study_id>
    <secondary_id>2015-003781-84</secondary_id>
    <nct_id>NCT02647281</nct_id>
  </id_info>
  <brief_title>First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, randomized, double-blind (Sponsor unblinded), placebo controlled,
      dose escalation study to determine the safety, tolerability and pharmacokinetics (PK) profile
      of GSK3389404 as single (Part 1) and multiple subcutaneous (SC) injections (Part 2) in
      healthy subjects. This study represents the first administration of GSK3389404 in humans to
      define the safety, tolerability and PK following single and multiple doses of GSK3389404 in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2015</start_date>
  <completion_date type="Actual">January 3, 2017</completion_date>
  <primary_completion_date type="Actual">January 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1</measure>
    <time_frame>Up to 62 days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. Participants who received any of the study treatment and had any AE or SAE or AELD were considered for analysis. Safety Population comprised of all participants who received at least 1 dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Non-serious AE; Any SAE; Any AELD in Part 2</measure>
    <time_frame>Up to 115 days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. Participants who received any of the study treatment and had any AE or SAE or AELD were considered for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Values of Potential Clinical Importance in Part 1</measure>
    <time_frame>Up to 62 days</time_frame>
    <description>Blood samples were collected for hematology, clinical chemistry, coagulation parameters and urinalysis. Abnormalities of potential clinical importance were evaluated as per Division of Acquired Immune Deficiency Syndrome [DAIDS] table for grading the severity of adult and pediatric adverse events. Laboratory abnormalities of DAIDS Grade 1 or higher were considered as of potential clinical importance and were summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Values of Potential Clinical Importance in Part 2</measure>
    <time_frame>Up to 115 days</time_frame>
    <description>Blood samples were collected for hematology, clinical chemistry, coagulation parameters and urinalysis. Abnormalities of potential clinical importance were evaluated as per DAIDS table for grading the severity of adult and pediatric adverse events. Laboratory abnormalities of DAIDS Grade 1 or higher were considered as of potential clinical importance and were summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Factor Component 3 (C3) and C4 Levels in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
    <description>Blood samples were collected to evaluate complement factors (C3 and C4) levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between minimum level (lowest of the measurements for specimens collected) observed post-dose and pre-study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Split Product C5a Levels in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
    <description>Blood samples were collected to evaluate complement split product C5a levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (highest of the measurements for specimens collected) observed post-dose and pre-study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Split Product Bb Levels in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
    <description>Blood samples were collected to evaluate complement split product Bb levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (highest of the measurements for specimens collected) observed post-dose and pre-study drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Factor C3 and C4 Levels in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and Day 22</time_frame>
    <description>Blood samples were collected to evaluate complement factors (C3 and C4) levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between minimum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Factor C5a Levels in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and Day 22</time_frame>
    <description>Blood samples were collected to evaluate complement factors C5a levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Factor Bb Levels in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and Day 22</time_frame>
    <description>Blood samples were collected to evaluate complement factors C5a levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
    <description>SBP and DBP were taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate (PR) at the Indicated Time Points in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
    <description>Pulse rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Respiratory Rate (RR) at the Indicated Time Points in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
    <description>Respiratory rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature at the Indicated Time Points in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
    <description>Temperature was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in SBP and DBP at the Indicated Time Points in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
    <description>SBP and DBP were taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113 +- 2 days). Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in PR at the Indicated Time Points in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
    <description>Pulse rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RR at the Indicated Time Points in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
    <description>Respiratory rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature at the Indicated Time Points in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
    <description>Body temperature was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 12-lead Electrocardiogram (ECG) Findings in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
    <description>12-lead ECGs were recorded at Baseline (Day 1, pre-dose) and at 1, 4, 8, 12, 24 and 48 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value. Number of participants with worst change from Baseline in ECG have been presented as clinically significant (CS) change or not a clinically significant (NCS) change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Curve (AUC) From Time Zero to Infinity [AUC (0-inf)], AUC From Time Zero to the Time of Last Quantifiable Concentration [AUC(0-t)], AUC From Time Zero to 24 Hours [AUC(0-24)] of GSK3389404 After Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate AUC (0-inf), AUC (0-t) and AUC (0-24) of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose. Pharmacokinetic Concentration Population was defined as participants who underwent plasma PK sampling and had evaluable PK assay results post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax), Observed Concentration at 24 Hours (C24) and at 168 Hours (C168) of GSK3389404 Following Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Cmax, C24 and C168 of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax), Terminal Half-life (T1/2) and Lag Time (Tlag) of GSK3389404 Following Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent SC Plasma Clearance (CL/F) of GSK3389404 Following Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate CL/F of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t), AUC(0-24), AUC From Time Zero to 168 Hours Post-dose [AUC(0-168)] and AUC (0-inf) of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate AUC (0-t), AUC (0-24), AUC (0-168) and AUC (0-inf) of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, C24 and C168 of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Cmax, C24 and C168 of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax, T1/2 and Tlag of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate CL/F of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose. Only those participants with data available at the specified time points were analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24) and AUC From Time Zero to the End of the Dosing Interval [AUC(0-tau)] of GSK3389404 Following Dosing on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate AUC (0-24) and AUC (0-tau) of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Concentration at the End of the Dosing Interval (Ctau), C24 and Cmax of GSK3389404 Following Dosing on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate Ctau, C24 and Cmax of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax, T1/2 and Tlag of GSK3389404 Following Dosing on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cl/F of GSK3389404 Following Dosing on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate Cl/F of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Proportionality of GSK202007 for Dose Range 10 mg - 120 mg After Single Dose Administrations</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose; Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose in Part 2.</time_frame>
    <description>Results of dose proportionality assessment using power model and analysis of variance (ANOVA) following single dose administariton (Part 1 and Day 1 in Part 2) are presented. Slope estimates and 90% confidence interval are presented for combined data of Day 1 of Part 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Proportionality of GSK202007 for Dose Range 30 mg - 120 mg After Multiple Dose Administrations</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115) in Part 2</time_frame>
    <description>Results of proportionality assessment using power model and ANOVA following multiple doses are presented. Slope estimates and 90% confidence interval are presented for Day 22 of Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio by AUC (RAUC), by Cmax (RCmax), by C24 (RC24) and by Ctau (RCtau) of GSK3389404 in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose; Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>For Part 2, the extent of accumulation of GSK3389404 was evaluated by comparing AUC (0-tau), Cmax, C24 and Ctau on Day 22 to AUC (0-168), Cmax, C24 and C168 on Day 1. For each dose level, a linear mixed effect model was fitted with the log transformed PK parameter as the dependent variable, day as a fixed effect and subject as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Invariance (LI) of GSK3389404 in Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose; Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>For Part 2, time invariance was evaluated by comparing AUC (0-tau) for Day 22 to AUC (0-inf) for Day 1. For each dose level, a linear mixed effect model was fitted with the log transformed PK parameter as the dependent variable, day as a fixed effect and subject as a random effect. Only those participants with data available at the specified time points were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentrations of GSK3389404 in Part 2</measure>
    <time_frame>Pre-dose on Days 8, 15, 22 and 29</time_frame>
    <description>For Part 2, mean plasma GSK3389404 pre-dose values between Day 1 to Day 29 and Ctau were plotted against time to assess attainment of GSK3389404 steady state following multiple dose administration. Achievement of plasma GSK3389404 steady-state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of log (Ctau) versus time. NA indicates data was not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-inf), AUC(0-t), AUC(0-24) of the Metabolite of GSK3389404 After Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate AUC (0-inf), AUC (0-t) and AUC (0-24) of metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Cmax, C24 and C168 of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose in Part 1</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-t), AUC(0-24), AUC(0-168) and AUC (0-inf) of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate AUC (0-t), AUC (0-24), AUC (0-168) and AUC (0-inf) of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Cmax, C24 and C168 of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</measure>
    <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
    <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24) and AUC(0-tau) of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate AUC (0-24) and AUC (0-tau) of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau, C24 and Cmax of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate Ctau, C24 and Cmax of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Dosing on Day 22 of Part 2</measure>
    <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
    <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Part 1: GSK3389404 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: GSK3389404 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: GSK3389404 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: GSK3389404 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GSK3389404 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GSK3389404 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: GSK3389404 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3389404</intervention_name>
    <description>GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.</description>
    <arm_group_label>Part 1: GSK3389404 10 mg</arm_group_label>
    <arm_group_label>Part 1: GSK3389404 120 mg</arm_group_label>
    <arm_group_label>Part 1: GSK3389404 30 mg</arm_group_label>
    <arm_group_label>Part 1: GSK3389404 60 mg</arm_group_label>
    <arm_group_label>Part 2: GSK3389404 120 mg</arm_group_label>
    <arm_group_label>Part 2: GSK3389404 30 mg</arm_group_label>
    <arm_group_label>Part 2: GSK3389404 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  The subject is able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions and is likely to complete the study as planned.

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             electrocardiograms (ECGs). There should be no evidence of cardiac, pulmonary, hepatic,
             biliary, gastrointestinal, or renal disorders, or cancer within the past 5 years
             (except localized or in situ cancer of the skin). A subject with a clinical
             abnormality or laboratory parameter(s) which is/are not specifically listed in the
             inclusion or exclusion criteria and are reported as outside of the normal reference
             range for healthy subjects may be included only if the Investigator considers the
             finding unlikely to introduce additional risk to the subject and will not interfere
             with the study procedures.

          -  Male or female between 18 and 55 years of age, inclusive, at the time of signing the
             informed consent form (ICF).

          -  Body weight &gt;50 kilograms (kg) (110 pounds [lb]) for men and &gt;45 kg (99 lb) women and
             a body mass index (BMI) between 18 to 30 kg/meter-squared, inclusive, will be allowed.

          -  AST, ALT, ALP, bilirubin, and creatinine within the normal reference range. If outside
             the normal reference range, these values may be repeated once at the discretion of the
             Investigator or designee.

          -  WBC count (including neutrophil counts), haemoglobin and platelets within the normal
             reference range. If outside the normal reference range, these values may be repeated
             once at the discretion of the Investigator or designee.

          -  Females of Reproductive Potential (FRP) are not permitted. Eligible females must meet
             the following criteria:

               -  Non-pregnant (as confirmed by a negative serum human chorionic gonadotrophin
                  (hCG) test); AND

               -  Non-lactating at screening and prior to dosing; AND

               -  Non-reproductive potential as defined by at least one of the following
                  conditions: Pre-menopausal females without reproductive potential defined by one
                  of the following: Documented salpingectomy, Hysterectomy, Documented bilateral
                  oophorectomy; Postmenopausal defined as 12 months of spontaneous amenorrhea; A
                  blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol
                  levels may be conducted at the discretion of the Investigator or site to confirm
                  non-reproductive potential.

          -  Male subjects with female partners of child-bearing potential must agree to meet one
             of the contraception requirements from the time of first dose of study treatment until
             the last follow-up visit (Part 1 Day 60; Part 2 Day 113).

               -  Vasectomy with documentation of azoospermia.

               -  Male condom plus partner use of one of the contraceptive options below that meets
                  the standard operating procedure (SOP) effectiveness criteria including a &lt;1%
                  rate of failure per year, as stated in the product label: Contraceptive subdermal
                  implant; Intrauterine device or intrauterine system; Combined estrogen and
                  progestogen oral contraceptive; Injectable progestogen; Contraceptive vaginal
                  ring; Percutaneous contraceptive patches These allowed methods of contraception
                  are only effective when used consistently, correctly and in accordance with the
                  product label. The Investigator is responsible for ensuring that subjects
                  understand how to properly use these methods of contraception.

        Exclusion Criteria:

          -  History or other clinical evidence of hypertension, significant or unstable cardiac
             disease (e.g., prolonged QT syndrome [torsade de pointes], angina, congestive heart
             failure, myocardial infarction, diastolic dysfunction, significant arrhythmia,
             coronary heart disease and/or clinically significant ECG abnormalities).

          -  History of, or active diagnosis of, liver disease such as Gilbert's syndrome,
             cirrhosis, autoimmune hepatitis, non-alcoholic fatty liver disease /non-alcoholic
             steatohepatitis, or hemochromatosis.

          -  History of, or active diagnosis of, primary or secondary (e.g., renal disease
             secondary to diabetes, hypertension, vascular disease, etc.) renal disease.

          -  History of bleeding diathesis or coagulopathy.

          -  History of regular alcohol consumption within 6 months of the study defined as: An
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is
             equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 milliliters [mL])
             of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.

          -  Unwilling to abstain from alcohol for 48 hours prior to the start of dosing until the
             last dose in each dosing session.

          -  Regular use of tobacco- or nicotine-containing products within 3 months prior to
             screening.

          -  History of sensitivity to GSK3389404 or components thereof or a history of drug or
             other allergy that, in the opinion of the investigator or GSK Medical Monitor,
             contraindicates their participation.

          -  Use of prescription or non-prescription drugs, including vitamin, dietary and herbal
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study treatment.

          -  Use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days prior
             to the first dose of study treatment.

          -  A positive hepatitis C antibody.

          -  A positive pre-study Hepatitis B surface antigen (HBsAg).

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Serum creatinine greater than the upper limit of normal (ULN)

          -  Glomerular filtration rate &lt;90 mL/minute as calculated by the Chronic Kidney Disease
             Epidemiology Collaboration (CKD-epi) formula

          -  Albumin to creatinine ratio (ACR) &gt;= 0.03 milligram/milligram (mg/mg). In the event of
             an ACR above this threshold, eligibility may be confirmed by a second measurement.

          -  Qualitative test (urinalysis) for blood in urine &gt;= 0.03 mg/deciliter. In the event of
             a positive test, the test may be repeated once, and if negative, the subject
             considered eligible.

          -  A positive pre-study drug screen. Unwilling to refrain from use of the illicit drugs
             and adhere to other protocol-stated restrictions while participating in the study.

          -  Fridericia's QT correction formula (QTcF) &gt;= 450 milliseconds (msec).

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 5 half-lives (if known) or twice the duration (if known) of the biological
             effect of the study drug (whichever is longer) or 90 days (if half-life or duration is
             unknown).

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA)
             within 12 months prior to the first dosing day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J, Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801. doi: 10.1002/cpdd.670. Epub 2019 Mar 12.</citation>
    <PMID>30861337</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <results_first_submitted>August 31, 2017</results_first_submitted>
  <results_first_submitted_qc>June 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2018</results_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Multiple ascending doses (MAD)</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>GSK3389404</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/SearchAllPostings.aspx?searchparam=202007</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a Phase 1, randomized, double-blind (sponsor un-blinded), placebo-controlled, dose escalation study to determine the safety, tolerability, and pharmacokinetic (PK) profile of GSK3389404 as single and multiple subcutaneous (SC) injections in healthy participants. This study was conducted at 2 centers in London, United Kingdom.</recruitment_details>
      <pre_assignment_details>The study was conducted in 2 Parts: Single-Ascending Dose (Part 1) and Multiple-Ascending Dose (Part 2). In Part 1, total of 32 participants were enrolled and all of them were randomized to receive the study treatment. In Part 2, a total of 24 participants were enrolled and all of them were randomized to receive the study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Placebo</title>
          <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: GSK3389404 10 mg</title>
          <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: GSK3389404 30 mg</title>
          <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: GSK3389404 60 mg</title>
          <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: GSK3389404 120 mg</title>
          <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 2: Placebo</title>
          <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
        </group>
        <group group_id="P7">
          <title>Part 2: GSK3389404 30 mg</title>
          <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="P8">
          <title>Part 2: GSK3389404 60 mg</title>
          <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="P9">
          <title>Part 2: GSK3389404 120 mg</title>
          <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Single-Ascending Dose(Part 1-62 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Multiple-Ascending Dose(Part 2-115 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Placebo</title>
          <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: GSK3389404 10 mg</title>
          <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: GSK3389404 30 mg</title>
          <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: GSK3389404 60 mg</title>
          <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: GSK3389404 120 mg</title>
          <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 2: Placebo</title>
          <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
        </group>
        <group group_id="B7">
          <title>Part 2: GSK3389404 30 mg</title>
          <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="B8">
          <title>Part 2: GSK3389404 60 mg</title>
          <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="B9">
          <title>Part 2: GSK3389404 120 mg</title>
          <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data for Part 1 is presented.</description>
          <population>N=32 for Part 1</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="8.22"/>
                    <measurement group_id="B2" value="27.5" spread="3.78"/>
                    <measurement group_id="B3" value="37.5" spread="12.44"/>
                    <measurement group_id="B4" value="32.8" spread="7.41"/>
                    <measurement group_id="B5" value="37.8" spread="13.41"/>
                    <measurement group_id="B10" value="32.5" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for Part 2 is presented.</description>
          <population>N=24 for Part 2</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="38.0" spread="11.78"/>
                    <measurement group_id="B7" value="32.2" spread="6.91"/>
                    <measurement group_id="B8" value="40.5" spread="11.13"/>
                    <measurement group_id="B9" value="38.5" spread="12.23"/>
                    <measurement group_id="B10" value="37.3" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity, Customized</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian-South East Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American/African heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-Central/South Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caribbean</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caribbean British</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. Participants who received any of the study treatment and had any AE or SAE or AELD were considered for analysis. Safety Population comprised of all participants who received at least 1 dose of study treatment.</description>
        <time_frame>Up to 62 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. Participants who received any of the study treatment and had any AE or SAE or AELD were considered for analysis. Safety Population comprised of all participants who received at least 1 dose of study treatment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AELD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Non-serious AE; Any SAE; Any AELD in Part 2</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. Participants who received any of the study treatment and had any AE or SAE or AELD were considered for analysis.</description>
        <time_frame>Up to 115 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Non-serious AE; Any SAE; Any AELD in Part 2</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or event associated with liver injury and impaired liver function were categorized as SAE. Participants who received any of the study treatment and had any AE or SAE or AELD were considered for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AELD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Values of Potential Clinical Importance in Part 1</title>
        <description>Blood samples were collected for hematology, clinical chemistry, coagulation parameters and urinalysis. Abnormalities of potential clinical importance were evaluated as per Division of Acquired Immune Deficiency Syndrome [DAIDS] table for grading the severity of adult and pediatric adverse events. Laboratory abnormalities of DAIDS Grade 1 or higher were considered as of potential clinical importance and were summarized.</description>
        <time_frame>Up to 62 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values of Potential Clinical Importance in Part 1</title>
          <description>Blood samples were collected for hematology, clinical chemistry, coagulation parameters and urinalysis. Abnormalities of potential clinical importance were evaluated as per Division of Acquired Immune Deficiency Syndrome [DAIDS] table for grading the severity of adult and pediatric adverse events. Laboratory abnormalities of DAIDS Grade 1 or higher were considered as of potential clinical importance and were summarized.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Values of Potential Clinical Importance in Part 2</title>
        <description>Blood samples were collected for hematology, clinical chemistry, coagulation parameters and urinalysis. Abnormalities of potential clinical importance were evaluated as per DAIDS table for grading the severity of adult and pediatric adverse events. Laboratory abnormalities of DAIDS Grade 1 or higher were considered as of potential clinical importance and were summarized.</description>
        <time_frame>Up to 115 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values of Potential Clinical Importance in Part 2</title>
          <description>Blood samples were collected for hematology, clinical chemistry, coagulation parameters and urinalysis. Abnormalities of potential clinical importance were evaluated as per DAIDS table for grading the severity of adult and pediatric adverse events. Laboratory abnormalities of DAIDS Grade 1 or higher were considered as of potential clinical importance and were summarized.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Factor Component 3 (C3) and C4 Levels in Part 1</title>
        <description>Blood samples were collected to evaluate complement factors (C3 and C4) levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between minimum level (lowest of the measurements for specimens collected) observed post-dose and pre-study drug administration.</description>
        <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Factor Component 3 (C3) and C4 Levels in Part 1</title>
          <description>Blood samples were collected to evaluate complement factors (C3 and C4) levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between minimum level (lowest of the measurements for specimens collected) observed post-dose and pre-study drug administration.</description>
          <population>Safety Population</population>
          <units>Gram per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0811" spread="0.09367"/>
                    <measurement group_id="O2" value="-0.0142" spread="0.04549"/>
                    <measurement group_id="O3" value="-0.1580" spread="0.12739"/>
                    <measurement group_id="O4" value="-0.0900" spread="0.07452"/>
                    <measurement group_id="O5" value="-0.0412" spread="0.06432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0320" spread="0.04107"/>
                    <measurement group_id="O2" value="-0.0123" spread="0.01768"/>
                    <measurement group_id="O3" value="-0.0600" spread="0.04544"/>
                    <measurement group_id="O4" value="-0.0212" spread="0.01987"/>
                    <measurement group_id="O5" value="-0.0250" spread="0.01979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Split Product C5a Levels in Part 1</title>
        <description>Blood samples were collected to evaluate complement split product C5a levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (highest of the measurements for specimens collected) observed post-dose and pre-study drug administration.</description>
        <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Split Product C5a Levels in Part 1</title>
          <description>Blood samples were collected to evaluate complement split product C5a levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (highest of the measurements for specimens collected) observed post-dose and pre-study drug administration.</description>
          <population>Safety Population</population>
          <units>Microgram per liter (ug/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.895" spread="4.6360"/>
                    <measurement group_id="O2" value="7.755" spread="8.8013"/>
                    <measurement group_id="O3" value="2.590" spread="1.9653"/>
                    <measurement group_id="O4" value="5.102" spread="18.7596"/>
                    <measurement group_id="O5" value="1.485" spread="2.5368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Split Product Bb Levels in Part 1</title>
        <description>Blood samples were collected to evaluate complement split product Bb levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (highest of the measurements for specimens collected) observed post-dose and pre-study drug administration</description>
        <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Split Product Bb Levels in Part 1</title>
          <description>Blood samples were collected to evaluate complement split product Bb levels. Latest pre-dose assessment at Day 1 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (highest of the measurements for specimens collected) observed post-dose and pre-study drug administration</description>
          <population>Safety Population</population>
          <units>mg per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8788" spread="1.01171"/>
                    <measurement group_id="O2" value="1.5517" spread="1.26063"/>
                    <measurement group_id="O3" value="0.6900" spread="0.48187"/>
                    <measurement group_id="O4" value="1.2900" spread="1.69068"/>
                    <measurement group_id="O5" value="0.3350" spread="0.78899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Factor C3 and C4 Levels in Part 2</title>
        <description>Blood samples were collected to evaluate complement factors (C3 and C4) levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between minimum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration</description>
        <time_frame>Day 1 (pre-dose) and Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Factor C3 and C4 Levels in Part 2</title>
          <description>Blood samples were collected to evaluate complement factors (C3 and C4) levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between minimum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration</description>
          <population>Safety Population</population>
          <units>G/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0495" spread="0.06661"/>
                    <measurement group_id="O2" value="-0.0333" spread="0.05961"/>
                    <measurement group_id="O3" value="-0.0783" spread="0.04025"/>
                    <measurement group_id="O4" value="-0.0293" spread="0.05722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C3, Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1143" spread="0.07139"/>
                    <measurement group_id="O2" value="-0.1013" spread="0.06017"/>
                    <measurement group_id="O3" value="-0.0840" spread="0.02521"/>
                    <measurement group_id="O4" value="-0.1702" spread="0.07908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0190" spread="0.01192"/>
                    <measurement group_id="O2" value="-0.0132" spread="0.03511"/>
                    <measurement group_id="O3" value="-0.0470" spread="0.02674"/>
                    <measurement group_id="O4" value="-0.0135" spread="0.01271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4, Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0397" spread="0.02043"/>
                    <measurement group_id="O2" value="-0.0405" spread="0.03661"/>
                    <measurement group_id="O3" value="-0.0390" spread="0.01980"/>
                    <measurement group_id="O4" value="-0.0443" spread="0.02805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Factor C5a Levels in Part 2</title>
        <description>Blood samples were collected to evaluate complement factors C5a levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration.</description>
        <time_frame>Day 1 (pre-dose) and Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Factor C5a Levels in Part 2</title>
          <description>Blood samples were collected to evaluate complement factors C5a levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration.</description>
          <population>Safety Population</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C5a, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" spread="4.2895"/>
                    <measurement group_id="O2" value="-1.167" spread="5.8963"/>
                    <measurement group_id="O3" value="2.750" spread="4.1563"/>
                    <measurement group_id="O4" value="11.083" spread="6.3907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C5a, Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.083" spread="4.2002"/>
                    <measurement group_id="O2" value="9.667" spread="10.5862"/>
                    <measurement group_id="O3" value="7.333" spread="2.3805"/>
                    <measurement group_id="O4" value="13.667" spread="9.9029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Factor Bb Levels in Part 2</title>
        <description>Blood samples were collected to evaluate complement factors C5a levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration.</description>
        <time_frame>Day 1 (pre-dose) and Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Factor Bb Levels in Part 2</title>
          <description>Blood samples were collected to evaluate complement factors C5a levels. Latest pre-dose assessment at Day 1 or Day 22 was considered as Baseline value. Change from Baseline was calculated as difference between maximum level (lowest of the measurements for specimens collected each after Day 1 and Day 22 study drug administrations) observed post-dose and pre-study drug administration.</description>
          <population>Safety Population</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bb, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4217" spread="0.62669"/>
                    <measurement group_id="O2" value="0.5033" spread="0.76727"/>
                    <measurement group_id="O3" value="0.9700" spread="0.60554"/>
                    <measurement group_id="O4" value="1.2667" spread="0.55623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bb, Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4003" spread="0.56580"/>
                    <measurement group_id="O2" value="1.3447" spread="0.75517"/>
                    <measurement group_id="O3" value="0.6833" spread="0.57597"/>
                    <measurement group_id="O4" value="1.7340" spread="1.05781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1</title>
        <description>SBP and DBP were taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1</title>
          <description>SBP and DBP were taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="6.53"/>
                    <measurement group_id="O2" value="-4.4" spread="4.38"/>
                    <measurement group_id="O3" value="-3.8" spread="7.36"/>
                    <measurement group_id="O4" value="1.5" spread="4.96"/>
                    <measurement group_id="O5" value="2.3" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="2.46"/>
                    <measurement group_id="O2" value="-3.1" spread="4.29"/>
                    <measurement group_id="O3" value="-4.8" spread="3.87"/>
                    <measurement group_id="O4" value="0.6" spread="3.64"/>
                    <measurement group_id="O5" value="-1.9" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="3.64"/>
                    <measurement group_id="O2" value="-5.6" spread="7.39"/>
                    <measurement group_id="O3" value="-0.6" spread="7.39"/>
                    <measurement group_id="O4" value="-0.8" spread="5.05"/>
                    <measurement group_id="O5" value="-0.4" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="3.66"/>
                    <measurement group_id="O2" value="-5.4" spread="8.78"/>
                    <measurement group_id="O3" value="-4.0" spread="7.93"/>
                    <measurement group_id="O4" value="-0.7" spread="4.43"/>
                    <measurement group_id="O5" value="-1.3" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="7.50"/>
                    <measurement group_id="O2" value="-5.8" spread="10.30"/>
                    <measurement group_id="O3" value="-3.8" spread="4.01"/>
                    <measurement group_id="O4" value="-1.5" spread="4.37"/>
                    <measurement group_id="O5" value="-1.4" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="4.29"/>
                    <measurement group_id="O2" value="-4.3" spread="7.53"/>
                    <measurement group_id="O3" value="0.2" spread="9.20"/>
                    <measurement group_id="O4" value="0.1" spread="4.00"/>
                    <measurement group_id="O5" value="-2.6" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="4.59"/>
                    <measurement group_id="O2" value="-3.3" spread="6.22"/>
                    <measurement group_id="O3" value="-3.0" spread="6.87"/>
                    <measurement group_id="O4" value="-1.3" spread="4.78"/>
                    <measurement group_id="O5" value="-1.4" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.38"/>
                    <measurement group_id="O2" value="-2.2" spread="5.71"/>
                    <measurement group_id="O3" value="1.0" spread="7.08"/>
                    <measurement group_id="O4" value="0.5" spread="1.25"/>
                    <measurement group_id="O5" value="-2.7" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="5.07"/>
                    <measurement group_id="O2" value="-3.4" spread="4.60"/>
                    <measurement group_id="O3" value="-4.6" spread="4.53"/>
                    <measurement group_id="O4" value="0.3" spread="7.33"/>
                    <measurement group_id="O5" value="-2.0" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="6.28"/>
                    <measurement group_id="O2" value="0.5" spread="7.36"/>
                    <measurement group_id="O3" value="-5.1" spread="6.92"/>
                    <measurement group_id="O4" value="2.1" spread="7.26"/>
                    <measurement group_id="O5" value="-0.3" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="7.65"/>
                    <measurement group_id="O2" value="-4.0" spread="3.85"/>
                    <measurement group_id="O3" value="-0.8" spread="8.55"/>
                    <measurement group_id="O4" value="1.8" spread="6.22"/>
                    <measurement group_id="O5" value="0.2" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="5.63"/>
                    <measurement group_id="O2" value="0.3" spread="5.89"/>
                    <measurement group_id="O3" value="2.2" spread="8.08"/>
                    <measurement group_id="O4" value="2.1" spread="5.51"/>
                    <measurement group_id="O5" value="4.9" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="4.58"/>
                    <measurement group_id="O2" value="-5.5" spread="6.42"/>
                    <measurement group_id="O3" value="-0.9" spread="4.32"/>
                    <measurement group_id="O4" value="-4.6" spread="7.68"/>
                    <measurement group_id="O5" value="0.3" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="6.27"/>
                    <measurement group_id="O2" value="-4.6" spread="11.61"/>
                    <measurement group_id="O3" value="-2.3" spread="5.31"/>
                    <measurement group_id="O4" value="1.2" spread="5.61"/>
                    <measurement group_id="O5" value="4.1" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="10.73"/>
                    <measurement group_id="O2" value="-5.5" spread="10.15"/>
                    <measurement group_id="O3" value="0.8" spread="4.58"/>
                    <measurement group_id="O4" value="-1.5" spread="7.04"/>
                    <measurement group_id="O5" value="2.2" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="6.40"/>
                    <measurement group_id="O2" value="-4.8" spread="6.42"/>
                    <measurement group_id="O3" value="3.1" spread="8.30"/>
                    <measurement group_id="O4" value="-0.6" spread="6.39"/>
                    <measurement group_id="O5" value="-0.9" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.84"/>
                    <measurement group_id="O2" value="-6.8" spread="5.48"/>
                    <measurement group_id="O3" value="-5.0" spread="3.89"/>
                    <measurement group_id="O4" value="-1.7" spread="4.07"/>
                    <measurement group_id="O5" value="-2.1" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="5.08"/>
                    <measurement group_id="O2" value="-2.8" spread="8.29"/>
                    <measurement group_id="O3" value="4.6" spread="9.89"/>
                    <measurement group_id="O4" value="0.6" spread="4.24"/>
                    <measurement group_id="O5" value="-1.5" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.41"/>
                    <measurement group_id="O2" value="-4.8" spread="4.87"/>
                    <measurement group_id="O3" value="-2.7" spread="5.98"/>
                    <measurement group_id="O4" value="0.5" spread="6.61"/>
                    <measurement group_id="O5" value="0.5" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="8.17"/>
                    <measurement group_id="O2" value="-1.7" spread="8.21"/>
                    <measurement group_id="O3" value="-0.1" spread="6.84"/>
                    <measurement group_id="O4" value="-0.9" spread="4.75"/>
                    <measurement group_id="O5" value="5.9" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate (PR) at the Indicated Time Points in Part 1</title>
        <description>Pulse rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate (PR) at the Indicated Time Points in Part 1</title>
          <description>Pulse rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.20"/>
                    <measurement group_id="O2" value="0.3" spread="5.49"/>
                    <measurement group_id="O3" value="-2.0" spread="3.19"/>
                    <measurement group_id="O4" value="1.5" spread="5.43"/>
                    <measurement group_id="O5" value="-3.2" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.68"/>
                    <measurement group_id="O2" value="4.0" spread="12.68"/>
                    <measurement group_id="O3" value="2.3" spread="4.54"/>
                    <measurement group_id="O4" value="3.8" spread="6.00"/>
                    <measurement group_id="O5" value="-2.3" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="5.83"/>
                    <measurement group_id="O2" value="-0.5" spread="7.68"/>
                    <measurement group_id="O3" value="-1.9" spread="3.24"/>
                    <measurement group_id="O4" value="0.2" spread="5.53"/>
                    <measurement group_id="O5" value="0.7" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.46"/>
                    <measurement group_id="O2" value="1.2" spread="4.50"/>
                    <measurement group_id="O3" value="1.9" spread="2.63"/>
                    <measurement group_id="O4" value="4.8" spread="5.89"/>
                    <measurement group_id="O5" value="1.3" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="12.49"/>
                    <measurement group_id="O2" value="1.6" spread="5.04"/>
                    <measurement group_id="O3" value="2.3" spread="4.19"/>
                    <measurement group_id="O4" value="8.6" spread="8.12"/>
                    <measurement group_id="O5" value="-0.7" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.49"/>
                    <measurement group_id="O2" value="-1.6" spread="9.89"/>
                    <measurement group_id="O3" value="1.4" spread="7.17"/>
                    <measurement group_id="O4" value="-1.3" spread="5.49"/>
                    <measurement group_id="O5" value="-0.9" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="10.74"/>
                    <measurement group_id="O2" value="0.2" spread="9.79"/>
                    <measurement group_id="O3" value="1.4" spread="4.46"/>
                    <measurement group_id="O4" value="2.3" spread="5.10"/>
                    <measurement group_id="O5" value="-0.6" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.85"/>
                    <measurement group_id="O2" value="1.0" spread="5.26"/>
                    <measurement group_id="O3" value="4.0" spread="3.47"/>
                    <measurement group_id="O4" value="5.3" spread="5.39"/>
                    <measurement group_id="O5" value="0.3" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="5.55"/>
                    <measurement group_id="O2" value="0.4" spread="6.34"/>
                    <measurement group_id="O3" value="1.4" spread="2.58"/>
                    <measurement group_id="O4" value="6.0" spread="7.36"/>
                    <measurement group_id="O5" value="1.5" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="6.53"/>
                    <measurement group_id="O2" value="4.3" spread="11.94"/>
                    <measurement group_id="O3" value="0.2" spread="5.36"/>
                    <measurement group_id="O4" value="6.3" spread="6.19"/>
                    <measurement group_id="O5" value="-1.1" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Respiratory Rate (RR) at the Indicated Time Points in Part 1</title>
        <description>Respiratory rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
        <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory Rate (RR) at the Indicated Time Points in Part 1</title>
          <description>Respiratory rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RR, 1 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.14"/>
                    <measurement group_id="O2" value="-1.3" spread="1.86"/>
                    <measurement group_id="O3" value="0.8" spread="3.54"/>
                    <measurement group_id="O4" value="1.5" spread="2.59"/>
                    <measurement group_id="O5" value="0.7" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 2 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.38"/>
                    <measurement group_id="O2" value="0.3" spread="3.14"/>
                    <measurement group_id="O3" value="-2.7" spread="2.66"/>
                    <measurement group_id="O4" value="1.0" spread="4.15"/>
                    <measurement group_id="O5" value="-1.7" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 4 hour, n=8, 6, 6, 5, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.01"/>
                    <measurement group_id="O2" value="-0.2" spread="2.14"/>
                    <measurement group_id="O3" value="0.0" spread="2.90"/>
                    <measurement group_id="O4" value="0.4" spread="5.50"/>
                    <measurement group_id="O5" value="0.2" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 8 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.95"/>
                    <measurement group_id="O2" value="-0.5" spread="1.87"/>
                    <measurement group_id="O3" value="-1.0" spread="3.79"/>
                    <measurement group_id="O4" value="-1.2" spread="3.87"/>
                    <measurement group_id="O5" value="-2.2" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 12 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.19"/>
                    <measurement group_id="O2" value="0.8" spread="1.60"/>
                    <measurement group_id="O3" value="-0.5" spread="2.59"/>
                    <measurement group_id="O4" value="0.0" spread="3.10"/>
                    <measurement group_id="O5" value="0.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 24 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.62"/>
                    <measurement group_id="O2" value="-0.3" spread="2.94"/>
                    <measurement group_id="O3" value="-2.2" spread="3.54"/>
                    <measurement group_id="O4" value="0.5" spread="1.52"/>
                    <measurement group_id="O5" value="-0.7" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 48 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.12"/>
                    <measurement group_id="O2" value="-0.8" spread="2.32"/>
                    <measurement group_id="O3" value="-2.0" spread="3.74"/>
                    <measurement group_id="O4" value="3.0" spread="3.29"/>
                    <measurement group_id="O5" value="1.7" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 72 hour, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.07"/>
                    <measurement group_id="O2" value="0.7" spread="3.44"/>
                    <measurement group_id="O3" value="0.0" spread="3.52"/>
                    <measurement group_id="O4" value="0.8" spread="3.66"/>
                    <measurement group_id="O5" value="-1.7" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 8, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.20"/>
                    <measurement group_id="O2" value="-1.3" spread="1.51"/>
                    <measurement group_id="O3" value="-1.5" spread="4.72"/>
                    <measurement group_id="O4" value="1.0" spread="2.97"/>
                    <measurement group_id="O5" value="-1.0" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 30, n=8, 6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.69"/>
                    <measurement group_id="O2" value="0.0" spread="1.41"/>
                    <measurement group_id="O3" value="-0.7" spread="3.44"/>
                    <measurement group_id="O4" value="-0.7" spread="3.50"/>
                    <measurement group_id="O5" value="-0.3" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Temperature at the Indicated Time Points in Part 1</title>
        <description>Temperature was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 30 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature at the Indicated Time Points in Part 1</title>
          <description>Temperature was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 8, 12, 24, 48 and 72 hour post dose; and on Days 8 and 30. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.185"/>
                    <measurement group_id="O2" value="0.00" spread="0.237"/>
                    <measurement group_id="O3" value="0.05" spread="0.122"/>
                    <measurement group_id="O4" value="0.10" spread="0.276"/>
                    <measurement group_id="O5" value="0.10" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.288"/>
                    <measurement group_id="O2" value="-0.02" spread="0.147"/>
                    <measurement group_id="O3" value="0.02" spread="0.172"/>
                    <measurement group_id="O4" value="-0.15" spread="0.243"/>
                    <measurement group_id="O5" value="0.05" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.213"/>
                    <measurement group_id="O2" value="0.08" spread="0.319"/>
                    <measurement group_id="O3" value="0.05" spread="0.217"/>
                    <measurement group_id="O4" value="-0.02" spread="0.264"/>
                    <measurement group_id="O5" value="0.08" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.297"/>
                    <measurement group_id="O2" value="-0.02" spread="0.279"/>
                    <measurement group_id="O3" value="0.20" spread="0.126"/>
                    <measurement group_id="O4" value="0.18" spread="0.147"/>
                    <measurement group_id="O5" value="0.23" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.255"/>
                    <measurement group_id="O2" value="0.03" spread="0.234"/>
                    <measurement group_id="O3" value="-0.03" spread="0.137"/>
                    <measurement group_id="O4" value="0.12" spread="0.204"/>
                    <measurement group_id="O5" value="0.08" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.290"/>
                    <measurement group_id="O2" value="-0.10" spread="0.167"/>
                    <measurement group_id="O3" value="-0.05" spread="0.152"/>
                    <measurement group_id="O4" value="0.07" spread="0.197"/>
                    <measurement group_id="O5" value="-0.03" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.434"/>
                    <measurement group_id="O2" value="-0.10" spread="0.210"/>
                    <measurement group_id="O3" value="0.03" spread="0.121"/>
                    <measurement group_id="O4" value="0.02" spread="0.248"/>
                    <measurement group_id="O5" value="-0.10" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.220"/>
                    <measurement group_id="O2" value="-0.07" spread="0.250"/>
                    <measurement group_id="O3" value="0.07" spread="0.225"/>
                    <measurement group_id="O4" value="0.07" spread="0.175"/>
                    <measurement group_id="O5" value="-0.03" spread="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.233"/>
                    <measurement group_id="O2" value="-0.08" spread="0.319"/>
                    <measurement group_id="O3" value="0.00" spread="0.200"/>
                    <measurement group_id="O4" value="-0.20" spread="0.228"/>
                    <measurement group_id="O5" value="0.05" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.177"/>
                    <measurement group_id="O2" value="-0.07" spread="0.216"/>
                    <measurement group_id="O3" value="0.00" spread="0.190"/>
                    <measurement group_id="O4" value="-0.07" spread="0.225"/>
                    <measurement group_id="O5" value="-0.12" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in SBP and DBP at the Indicated Time Points in Part 2</title>
        <description>SBP and DBP were taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113 +- 2 days). Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
        <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP and DBP at the Indicated Time Points in Part 2</title>
          <description>SBP and DBP were taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113 +- 2 days). Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, Day 1, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="4.75"/>
                    <measurement group_id="O2" value="5.7" spread="4.83"/>
                    <measurement group_id="O3" value="-1.8" spread="3.49"/>
                    <measurement group_id="O4" value="-2.4" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 2 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="5.56"/>
                    <measurement group_id="O2" value="-0.1" spread="4.83"/>
                    <measurement group_id="O3" value="-0.8" spread="6.74"/>
                    <measurement group_id="O4" value="-1.6" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="5.54"/>
                    <measurement group_id="O2" value="-5.1" spread="6.25"/>
                    <measurement group_id="O3" value="-4.6" spread="5.86"/>
                    <measurement group_id="O4" value="-8.0" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.51"/>
                    <measurement group_id="O2" value="-2.6" spread="6.90"/>
                    <measurement group_id="O3" value="-3.5" spread="5.03"/>
                    <measurement group_id="O4" value="-5.1" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="6.66"/>
                    <measurement group_id="O2" value="1.4" spread="4.12"/>
                    <measurement group_id="O3" value="-3.0" spread="8.63"/>
                    <measurement group_id="O4" value="-4.1" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="7.17"/>
                    <measurement group_id="O2" value="-2.6" spread="4.49"/>
                    <measurement group_id="O3" value="-7.7" spread="5.97"/>
                    <measurement group_id="O4" value="-4.4" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 2, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="6.29"/>
                    <measurement group_id="O2" value="0.9" spread="3.36"/>
                    <measurement group_id="O3" value="-3.0" spread="4.87"/>
                    <measurement group_id="O4" value="-2.1" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 3, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.41"/>
                    <measurement group_id="O2" value="2.6" spread="5.55"/>
                    <measurement group_id="O3" value="-4.8" spread="5.24"/>
                    <measurement group_id="O4" value="-2.6" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 4, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="5.77"/>
                    <measurement group_id="O2" value="-6.1" spread="6.56"/>
                    <measurement group_id="O3" value="-1.9" spread="3.09"/>
                    <measurement group_id="O4" value="-0.1" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 8, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="7.61"/>
                    <measurement group_id="O2" value="1.9" spread="5.59"/>
                    <measurement group_id="O3" value="-2.6" spread="3.82"/>
                    <measurement group_id="O4" value="-3.0" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 15, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="11.22"/>
                    <measurement group_id="O2" value="5.5" spread="3.60"/>
                    <measurement group_id="O3" value="2.6" spread="6.70"/>
                    <measurement group_id="O4" value="-3.1" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 22, pre-dose, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="7.07"/>
                    <measurement group_id="O2" value="-3.8" spread="4.91"/>
                    <measurement group_id="O3" value="-3.1" spread="1.66"/>
                    <measurement group_id="O4" value="-2.2" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 22, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="6.79"/>
                    <measurement group_id="O2" value="-0.8" spread="7.56"/>
                    <measurement group_id="O3" value="-2.3" spread="6.39"/>
                    <measurement group_id="O4" value="-1.8" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 22, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="7.53"/>
                    <measurement group_id="O2" value="-0.3" spread="6.34"/>
                    <measurement group_id="O3" value="-4.8" spread="6.46"/>
                    <measurement group_id="O4" value="-3.4" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 22, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="6.22"/>
                    <measurement group_id="O2" value="0.1" spread="5.44"/>
                    <measurement group_id="O3" value="-9.3" spread="8.96"/>
                    <measurement group_id="O4" value="-4.2" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 22, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="5.82"/>
                    <measurement group_id="O2" value="-2.8" spread="6.29"/>
                    <measurement group_id="O3" value="-4.4" spread="7.14"/>
                    <measurement group_id="O4" value="-1.2" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 22, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="7.80"/>
                    <measurement group_id="O2" value="-2.9" spread="3.01"/>
                    <measurement group_id="O3" value="-7.0" spread="9.15"/>
                    <measurement group_id="O4" value="-2.6" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 23, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="8.59"/>
                    <measurement group_id="O2" value="-4.2" spread="6.14"/>
                    <measurement group_id="O3" value="-4.5" spread="4.00"/>
                    <measurement group_id="O4" value="-0.6" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 24, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="5.84"/>
                    <measurement group_id="O2" value="-2.8" spread="5.32"/>
                    <measurement group_id="O3" value="-1.7" spread="4.30"/>
                    <measurement group_id="O4" value="-0.9" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 25, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="6.71"/>
                    <measurement group_id="O2" value="0.7" spread="3.88"/>
                    <measurement group_id="O3" value="0.4" spread="2.83"/>
                    <measurement group_id="O4" value="0.1" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 29, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="9.06"/>
                    <measurement group_id="O2" value="5.7" spread="7.45"/>
                    <measurement group_id="O3" value="1.1" spread="4.70"/>
                    <measurement group_id="O4" value="-2.9" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 36, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="8.10"/>
                    <measurement group_id="O2" value="4.3" spread="7.05"/>
                    <measurement group_id="O3" value="1.7" spread="4.67"/>
                    <measurement group_id="O4" value="2.6" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 50, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="3.93"/>
                    <measurement group_id="O2" value="9.7" spread="7.90"/>
                    <measurement group_id="O3" value="2.9" spread="4.39"/>
                    <measurement group_id="O4" value="-0.1" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 71, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="6.27"/>
                    <measurement group_id="O2" value="8.9" spread="6.31"/>
                    <measurement group_id="O3" value="2.4" spread="3.94"/>
                    <measurement group_id="O4" value="4.0" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Follow-up, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="6.38"/>
                    <measurement group_id="O2" value="2.2" spread="6.54"/>
                    <measurement group_id="O3" value="4.3" spread="3.85"/>
                    <measurement group_id="O4" value="7.7" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="5.55"/>
                    <measurement group_id="O2" value="3.4" spread="6.83"/>
                    <measurement group_id="O3" value="1.1" spread="5.35"/>
                    <measurement group_id="O4" value="5.3" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 2 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="5.95"/>
                    <measurement group_id="O2" value="0.5" spread="2.99"/>
                    <measurement group_id="O3" value="-0.6" spread="3.38"/>
                    <measurement group_id="O4" value="3.9" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="6.36"/>
                    <measurement group_id="O2" value="-2.6" spread="2.16"/>
                    <measurement group_id="O3" value="-4.6" spread="6.57"/>
                    <measurement group_id="O4" value="0.4" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="6.23"/>
                    <measurement group_id="O2" value="-0.9" spread="3.71"/>
                    <measurement group_id="O3" value="-1.6" spread="6.54"/>
                    <measurement group_id="O4" value="5.4" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.26"/>
                    <measurement group_id="O2" value="0.6" spread="3.65"/>
                    <measurement group_id="O3" value="0.4" spread="10.56"/>
                    <measurement group_id="O4" value="5.8" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="6.39"/>
                    <measurement group_id="O2" value="-0.4" spread="5.32"/>
                    <measurement group_id="O3" value="-2.9" spread="7.54"/>
                    <measurement group_id="O4" value="5.8" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 2, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="6.25"/>
                    <measurement group_id="O2" value="-0.1" spread="4.35"/>
                    <measurement group_id="O3" value="0.4" spread="4.95"/>
                    <measurement group_id="O4" value="2.4" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 3, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="8.69"/>
                    <measurement group_id="O2" value="1.5" spread="6.13"/>
                    <measurement group_id="O3" value="-2.4" spread="6.34"/>
                    <measurement group_id="O4" value="5.0" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 4, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="4.96"/>
                    <measurement group_id="O2" value="-3.7" spread="6.64"/>
                    <measurement group_id="O3" value="0.2" spread="7.29"/>
                    <measurement group_id="O4" value="7.5" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 8, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="7.45"/>
                    <measurement group_id="O2" value="-1.7" spread="6.25"/>
                    <measurement group_id="O3" value="-4.4" spread="5.97"/>
                    <measurement group_id="O4" value="2.8" spread="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 15, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="10.88"/>
                    <measurement group_id="O2" value="4.6" spread="7.93"/>
                    <measurement group_id="O3" value="-2.3" spread="6.47"/>
                    <measurement group_id="O4" value="1.5" spread="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 22, pre-dose, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="9.18"/>
                    <measurement group_id="O2" value="-4.6" spread="5.69"/>
                    <measurement group_id="O3" value="-4.0" spread="2.60"/>
                    <measurement group_id="O4" value="-1.1" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 22, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="6.34"/>
                    <measurement group_id="O2" value="-4.6" spread="4.41"/>
                    <measurement group_id="O3" value="-1.6" spread="2.20"/>
                    <measurement group_id="O4" value="3.2" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 22, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="6.11"/>
                    <measurement group_id="O2" value="-2.0" spread="4.70"/>
                    <measurement group_id="O3" value="-4.2" spread="5.24"/>
                    <measurement group_id="O4" value="2.5" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 22, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="7.57"/>
                    <measurement group_id="O2" value="-2.7" spread="2.55"/>
                    <measurement group_id="O3" value="-6.1" spread="7.77"/>
                    <measurement group_id="O4" value="1.3" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 22, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="5.73"/>
                    <measurement group_id="O2" value="-5.9" spread="2.98"/>
                    <measurement group_id="O3" value="-5.4" spread="6.27"/>
                    <measurement group_id="O4" value="0.6" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 22, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="6.14"/>
                    <measurement group_id="O2" value="0.1" spread="3.22"/>
                    <measurement group_id="O3" value="-5.2" spread="8.57"/>
                    <measurement group_id="O4" value="5.2" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 23, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="8.50"/>
                    <measurement group_id="O2" value="-5.7" spread="3.77"/>
                    <measurement group_id="O3" value="-1.2" spread="5.67"/>
                    <measurement group_id="O4" value="4.9" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 24, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.79"/>
                    <measurement group_id="O2" value="-7.4" spread="4.48"/>
                    <measurement group_id="O3" value="-0.8" spread="5.02"/>
                    <measurement group_id="O4" value="2.8" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 25, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="5.37"/>
                    <measurement group_id="O2" value="-1.0" spread="3.48"/>
                    <measurement group_id="O3" value="4.4" spread="5.69"/>
                    <measurement group_id="O4" value="5.0" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 29, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.24"/>
                    <measurement group_id="O2" value="6.8" spread="7.69"/>
                    <measurement group_id="O3" value="-1.0" spread="4.68"/>
                    <measurement group_id="O4" value="1.9" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 36, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="9.99"/>
                    <measurement group_id="O2" value="4.2" spread="7.35"/>
                    <measurement group_id="O3" value="0.7" spread="6.11"/>
                    <measurement group_id="O4" value="3.2" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 50, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="6.28"/>
                    <measurement group_id="O2" value="3.9" spread="4.47"/>
                    <measurement group_id="O3" value="-0.7" spread="7.20"/>
                    <measurement group_id="O4" value="2.5" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 71, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="7.49"/>
                    <measurement group_id="O2" value="4.9" spread="7.81"/>
                    <measurement group_id="O3" value="4.1" spread="7.42"/>
                    <measurement group_id="O4" value="7.4" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Follow-up, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="8.05"/>
                    <measurement group_id="O2" value="-2.1" spread="7.16"/>
                    <measurement group_id="O3" value="10.0" spread="5.98"/>
                    <measurement group_id="O4" value="11.5" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in PR at the Indicated Time Points in Part 2</title>
        <description>Pulse rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
        <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR at the Indicated Time Points in Part 2</title>
          <description>Pulse rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Measurements were obtained after resting for at least 5 minutes in a semi-supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR, Day 1, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="7.15"/>
                    <measurement group_id="O2" value="0.5" spread="3.80"/>
                    <measurement group_id="O3" value="0.3" spread="1.54"/>
                    <measurement group_id="O4" value="-2.4" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 1, 2 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.57"/>
                    <measurement group_id="O2" value="-1.6" spread="6.79"/>
                    <measurement group_id="O3" value="2.9" spread="4.17"/>
                    <measurement group_id="O4" value="-1.1" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 1, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="4.13"/>
                    <measurement group_id="O2" value="4.6" spread="5.99"/>
                    <measurement group_id="O3" value="6.6" spread="3.75"/>
                    <measurement group_id="O4" value="2.4" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 1, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="2.38"/>
                    <measurement group_id="O2" value="5.8" spread="7.12"/>
                    <measurement group_id="O3" value="7.9" spread="3.27"/>
                    <measurement group_id="O4" value="6.6" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 1, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.83"/>
                    <measurement group_id="O2" value="3.5" spread="5.39"/>
                    <measurement group_id="O3" value="7.8" spread="6.99"/>
                    <measurement group_id="O4" value="0.5" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 1, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.29"/>
                    <measurement group_id="O2" value="7.2" spread="7.13"/>
                    <measurement group_id="O3" value="7.8" spread="6.09"/>
                    <measurement group_id="O4" value="3.9" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 2, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="4.62"/>
                    <measurement group_id="O2" value="-2.4" spread="4.84"/>
                    <measurement group_id="O3" value="2.4" spread="3.33"/>
                    <measurement group_id="O4" value="-1.1" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 3, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.90"/>
                    <measurement group_id="O2" value="4.3" spread="9.58"/>
                    <measurement group_id="O3" value="6.2" spread="5.70"/>
                    <measurement group_id="O4" value="-0.1" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 4, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="8.83"/>
                    <measurement group_id="O2" value="5.7" spread="5.30"/>
                    <measurement group_id="O3" value="10.8" spread="8.06"/>
                    <measurement group_id="O4" value="4.0" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 8, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.11"/>
                    <measurement group_id="O2" value="1.6" spread="8.20"/>
                    <measurement group_id="O3" value="7.1" spread="6.86"/>
                    <measurement group_id="O4" value="-1.6" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 15, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="10.22"/>
                    <measurement group_id="O2" value="4.9" spread="12.25"/>
                    <measurement group_id="O3" value="2.4" spread="3.52"/>
                    <measurement group_id="O4" value="-5.7" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 22, pre-dose, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="6.80"/>
                    <measurement group_id="O2" value="8.0" spread="14.84"/>
                    <measurement group_id="O3" value="1.5" spread="1.59"/>
                    <measurement group_id="O4" value="-2.9" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 22, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="4.84"/>
                    <measurement group_id="O2" value="-3.1" spread="4.22"/>
                    <measurement group_id="O3" value="2.2" spread="3.35"/>
                    <measurement group_id="O4" value="-3.2" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 22, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="4.01"/>
                    <measurement group_id="O2" value="4.3" spread="5.87"/>
                    <measurement group_id="O3" value="11.5" spread="10.74"/>
                    <measurement group_id="O4" value="2.6" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 22, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="3.75"/>
                    <measurement group_id="O2" value="3.8" spread="1.81"/>
                    <measurement group_id="O3" value="8.6" spread="3.98"/>
                    <measurement group_id="O4" value="2.4" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 22, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="6.26"/>
                    <measurement group_id="O2" value="-1.6" spread="5.59"/>
                    <measurement group_id="O3" value="5.7" spread="3.61"/>
                    <measurement group_id="O4" value="-2.1" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 22, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="4.03"/>
                    <measurement group_id="O2" value="5.4" spread="4.64"/>
                    <measurement group_id="O3" value="9.3" spread="4.47"/>
                    <measurement group_id="O4" value="7.9" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 23, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.46"/>
                    <measurement group_id="O2" value="0.0" spread="4.92"/>
                    <measurement group_id="O3" value="4.6" spread="6.63"/>
                    <measurement group_id="O4" value="0.7" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 24, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.88"/>
                    <measurement group_id="O2" value="-1.0" spread="4.85"/>
                    <measurement group_id="O3" value="3.6" spread="3.79"/>
                    <measurement group_id="O4" value="2.9" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 25, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="10.05"/>
                    <measurement group_id="O2" value="7.1" spread="5.05"/>
                    <measurement group_id="O3" value="7.0" spread="4.94"/>
                    <measurement group_id="O4" value="4.3" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 29, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="4.76"/>
                    <measurement group_id="O2" value="6.9" spread="8.33"/>
                    <measurement group_id="O3" value="5.0" spread="1.14"/>
                    <measurement group_id="O4" value="-0.6" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 36, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="6.54"/>
                    <measurement group_id="O2" value="5.4" spread="7.51"/>
                    <measurement group_id="O3" value="3.8" spread="6.10"/>
                    <measurement group_id="O4" value="-3.2" spread="13.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 50, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="4.85"/>
                    <measurement group_id="O2" value="1.1" spread="2.09"/>
                    <measurement group_id="O3" value="2.2" spread="6.51"/>
                    <measurement group_id="O4" value="-7.0" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Day 71, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.74"/>
                    <measurement group_id="O2" value="5.1" spread="7.39"/>
                    <measurement group_id="O3" value="6.0" spread="2.04"/>
                    <measurement group_id="O4" value="-1.9" spread="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, Follow-up, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="6.79"/>
                    <measurement group_id="O2" value="2.7" spread="5.08"/>
                    <measurement group_id="O3" value="6.0" spread="4.23"/>
                    <measurement group_id="O4" value="2.0" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RR at the Indicated Time Points in Part 2</title>
        <description>Respiratory rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
        <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RR at the Indicated Time Points in Part 2</title>
          <description>Respiratory rate was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RR, Day 1, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.97"/>
                    <measurement group_id="O2" value="0.7" spread="2.73"/>
                    <measurement group_id="O3" value="0.0" spread="1.26"/>
                    <measurement group_id="O4" value="0.5" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 1, 2 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.97"/>
                    <measurement group_id="O2" value="-0.3" spread="2.34"/>
                    <measurement group_id="O3" value="0.7" spread="1.63"/>
                    <measurement group_id="O4" value="0.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 1, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.35"/>
                    <measurement group_id="O2" value="1.0" spread="3.52"/>
                    <measurement group_id="O3" value="-0.7" spread="2.42"/>
                    <measurement group_id="O4" value="-0.5" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 1, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.66"/>
                    <measurement group_id="O2" value="1.3" spread="4.13"/>
                    <measurement group_id="O3" value="2.0" spread="2.53"/>
                    <measurement group_id="O4" value="-0.5" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 1, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.73"/>
                    <measurement group_id="O2" value="1.3" spread="3.01"/>
                    <measurement group_id="O3" value="0.7" spread="2.42"/>
                    <measurement group_id="O4" value="0.8" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 1, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.79"/>
                    <measurement group_id="O2" value="1.7" spread="2.66"/>
                    <measurement group_id="O3" value="3.3" spread="2.42"/>
                    <measurement group_id="O4" value="0.5" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 2, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.42"/>
                    <measurement group_id="O2" value="1.0" spread="2.10"/>
                    <measurement group_id="O3" value="-1.7" spread="1.51"/>
                    <measurement group_id="O4" value="-0.5" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 3, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.10"/>
                    <measurement group_id="O2" value="-0.3" spread="2.34"/>
                    <measurement group_id="O3" value="-1.0" spread="2.76"/>
                    <measurement group_id="O4" value="-0.8" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 4, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.71"/>
                    <measurement group_id="O2" value="1.3" spread="3.67"/>
                    <measurement group_id="O3" value="0.3" spread="3.44"/>
                    <measurement group_id="O4" value="-0.2" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 8, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.63"/>
                    <measurement group_id="O2" value="-0.3" spread="3.88"/>
                    <measurement group_id="O3" value="1.3" spread="3.72"/>
                    <measurement group_id="O4" value="-0.8" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 15, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.63"/>
                    <measurement group_id="O2" value="1.5" spread="1.76"/>
                    <measurement group_id="O3" value="0.7" spread="2.42"/>
                    <measurement group_id="O4" value="-0.8" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 22, pre-dose, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.79"/>
                    <measurement group_id="O2" value="0.7" spread="2.42"/>
                    <measurement group_id="O3" value="-1.0" spread="2.45"/>
                    <measurement group_id="O4" value="-0.5" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 22, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.27"/>
                    <measurement group_id="O2" value="0.3" spread="3.88"/>
                    <measurement group_id="O3" value="-0.3" spread="3.88"/>
                    <measurement group_id="O4" value="0.5" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 22, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.63"/>
                    <measurement group_id="O2" value="1.8" spread="4.02"/>
                    <measurement group_id="O3" value="-1.0" spread="3.74"/>
                    <measurement group_id="O4" value="0.8" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 22, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.10"/>
                    <measurement group_id="O2" value="2.3" spread="3.88"/>
                    <measurement group_id="O3" value="3.0" spread="2.76"/>
                    <measurement group_id="O4" value="0.2" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 22, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.97"/>
                    <measurement group_id="O2" value="2.7" spread="3.50"/>
                    <measurement group_id="O3" value="-0.7" spread="2.07"/>
                    <measurement group_id="O4" value="-0.8" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 22, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.20"/>
                    <measurement group_id="O2" value="4.3" spread="3.20"/>
                    <measurement group_id="O3" value="1.0" spread="2.10"/>
                    <measurement group_id="O4" value="-1.5" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 23, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.50"/>
                    <measurement group_id="O2" value="1.3" spread="2.73"/>
                    <measurement group_id="O3" value="-0.3" spread="2.94"/>
                    <measurement group_id="O4" value="-0.5" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 24, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.03"/>
                    <measurement group_id="O2" value="1.7" spread="2.94"/>
                    <measurement group_id="O3" value="-0.3" spread="2.66"/>
                    <measurement group_id="O4" value="-0.5" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 25, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.76"/>
                    <measurement group_id="O2" value="2.7" spread="2.42"/>
                    <measurement group_id="O3" value="-0.7" spread="3.01"/>
                    <measurement group_id="O4" value="-1.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 29, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.63"/>
                    <measurement group_id="O2" value="1.3" spread="2.73"/>
                    <measurement group_id="O3" value="-1.0" spread="1.67"/>
                    <measurement group_id="O4" value="-0.2" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 36, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.10"/>
                    <measurement group_id="O2" value="0.7" spread="3.27"/>
                    <measurement group_id="O3" value="0.0" spread="3.35"/>
                    <measurement group_id="O4" value="-1.0" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 50, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.56"/>
                    <measurement group_id="O2" value="1.0" spread="3.74"/>
                    <measurement group_id="O3" value="-0.7" spread="3.27"/>
                    <measurement group_id="O4" value="-0.2" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Day 71, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.40"/>
                    <measurement group_id="O2" value="1.3" spread="1.03"/>
                    <measurement group_id="O3" value="0.0" spread="4.00"/>
                    <measurement group_id="O4" value="0.6" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, Follow-up, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.51"/>
                    <measurement group_id="O2" value="-1.0" spread="1.67"/>
                    <measurement group_id="O3" value="-0.7" spread="3.50"/>
                    <measurement group_id="O4" value="0.6" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Temperature at the Indicated Time Points in Part 2</title>
        <description>Body temperature was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
        <time_frame>Day 1 (pre-dose) and up to 115 days</time_frame>
        <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature at the Indicated Time Points in Part 2</title>
          <description>Body temperature was taken at Baseline (Day 1, pre-dose) and at 1, 2, 4, 6, 8, 12, 24, 48 and 72 hour post Day 1 dose; on Days 8 and 15; Day 22 (pre-dose) and at 1, 4, 6, 12, 24, 48 and 72 hours post Day 22 dose; on Days 29, 36, 50, 71 and at Follow-up visit (Day 113+- 2 days). Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value.</description>
          <population>Safety Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, Day 1, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.388"/>
                    <measurement group_id="O2" value="0.15" spread="0.288"/>
                    <measurement group_id="O3" value="-0.05" spread="0.176"/>
                    <measurement group_id="O4" value="0.02" spread="0.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 1, 2 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.167"/>
                    <measurement group_id="O2" value="-0.02" spread="0.256"/>
                    <measurement group_id="O3" value="0.05" spread="0.187"/>
                    <measurement group_id="O4" value="-0.02" spread="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 1, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.110"/>
                    <measurement group_id="O2" value="0.35" spread="0.308"/>
                    <measurement group_id="O3" value="0.02" spread="0.117"/>
                    <measurement group_id="O4" value="0.15" spread="0.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 1, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.325"/>
                    <measurement group_id="O2" value="0.38" spread="0.454"/>
                    <measurement group_id="O3" value="0.10" spread="0.237"/>
                    <measurement group_id="O4" value="0.20" spread="0.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 1, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.228"/>
                    <measurement group_id="O2" value="0.43" spread="0.408"/>
                    <measurement group_id="O3" value="-0.13" spread="0.320"/>
                    <measurement group_id="O4" value="0.33" spread="0.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 1, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.147"/>
                    <measurement group_id="O2" value="0.50" spread="0.369"/>
                    <measurement group_id="O3" value="-0.15" spread="0.295"/>
                    <measurement group_id="O4" value="0.20" spread="0.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 2, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.321"/>
                    <measurement group_id="O2" value="-0.10" spread="0.379"/>
                    <measurement group_id="O3" value="-0.18" spread="0.223"/>
                    <measurement group_id="O4" value="-0.15" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 3, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.442"/>
                    <measurement group_id="O2" value="0.15" spread="0.489"/>
                    <measurement group_id="O3" value="-0.22" spread="0.204"/>
                    <measurement group_id="O4" value="-0.32" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 4, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.362"/>
                    <measurement group_id="O2" value="0.28" spread="0.595"/>
                    <measurement group_id="O3" value="0.30" spread="0.210"/>
                    <measurement group_id="O4" value="-0.02" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 8, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.436"/>
                    <measurement group_id="O2" value="0.05" spread="0.235"/>
                    <measurement group_id="O3" value="0.10" spread="0.283"/>
                    <measurement group_id="O4" value="-0.20" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 15, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.446"/>
                    <measurement group_id="O2" value="0.08" spread="0.376"/>
                    <measurement group_id="O3" value="-0.05" spread="0.197"/>
                    <measurement group_id="O4" value="-0.12" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 22, pre-dose, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.488"/>
                    <measurement group_id="O2" value="-0.02" spread="0.331"/>
                    <measurement group_id="O3" value="-0.22" spread="0.183"/>
                    <measurement group_id="O4" value="-0.23" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 22, 1 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.266"/>
                    <measurement group_id="O2" value="-0.15" spread="0.315"/>
                    <measurement group_id="O3" value="-0.07" spread="0.175"/>
                    <measurement group_id="O4" value="-0.20" spread="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 22, 4 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.422"/>
                    <measurement group_id="O2" value="0.13" spread="0.513"/>
                    <measurement group_id="O3" value="0.07" spread="0.242"/>
                    <measurement group_id="O4" value="-0.18" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 22, 6 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.306"/>
                    <measurement group_id="O2" value="0.28" spread="0.248"/>
                    <measurement group_id="O3" value="0.17" spread="0.163"/>
                    <measurement group_id="O4" value="-0.02" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 22, 8 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.217"/>
                    <measurement group_id="O2" value="0.23" spread="0.367"/>
                    <measurement group_id="O3" value="-0.05" spread="0.243"/>
                    <measurement group_id="O4" value="-0.02" spread="0.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 22, 12 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.366"/>
                    <measurement group_id="O2" value="0.08" spread="0.299"/>
                    <measurement group_id="O3" value="0.27" spread="0.344"/>
                    <measurement group_id="O4" value="0.22" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 23, 24 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.366"/>
                    <measurement group_id="O2" value="0.15" spread="0.536"/>
                    <measurement group_id="O3" value="-0.13" spread="0.216"/>
                    <measurement group_id="O4" value="-0.12" spread="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 24, 48 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.417"/>
                    <measurement group_id="O2" value="0.00" spread="0.352"/>
                    <measurement group_id="O3" value="-0.08" spread="0.098"/>
                    <measurement group_id="O4" value="-0.13" spread="0.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 25, 72 hour, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.276"/>
                    <measurement group_id="O2" value="0.20" spread="0.562"/>
                    <measurement group_id="O3" value="0.12" spread="0.445"/>
                    <measurement group_id="O4" value="-0.20" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 29, n=6, 6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.366"/>
                    <measurement group_id="O2" value="-0.05" spread="0.187"/>
                    <measurement group_id="O3" value="-0.15" spread="0.266"/>
                    <measurement group_id="O4" value="-0.23" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 36, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.271"/>
                    <measurement group_id="O2" value="0.03" spread="0.350"/>
                    <measurement group_id="O3" value="-0.20" spread="0.385"/>
                    <measurement group_id="O4" value="-0.16" spread="0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 50, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.325"/>
                    <measurement group_id="O2" value="-0.07" spread="0.480"/>
                    <measurement group_id="O3" value="-0.37" spread="0.121"/>
                    <measurement group_id="O4" value="0.04" spread="0.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Day 71, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.286"/>
                    <measurement group_id="O2" value="-0.13" spread="0.378"/>
                    <measurement group_id="O3" value="-0.53" spread="0.280"/>
                    <measurement group_id="O4" value="-0.34" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, Follow-up, n=6, 6, 6, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.479"/>
                    <measurement group_id="O2" value="0.08" spread="0.397"/>
                    <measurement group_id="O3" value="-0.12" spread="0.293"/>
                    <measurement group_id="O4" value="-0.02" spread="0.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 12-lead Electrocardiogram (ECG) Findings in Part 1</title>
        <description>12-lead ECGs were recorded at Baseline (Day 1, pre-dose) and at 1, 4, 8, 12, 24 and 48 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value. Number of participants with worst change from Baseline in ECG have been presented as clinically significant (CS) change or not a clinically significant (NCS) change.</description>
        <time_frame>Day 1 (pre-dose) and up to 31 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 12-lead Electrocardiogram (ECG) Findings in Part 1</title>
          <description>12-lead ECGs were recorded at Baseline (Day 1, pre-dose) and at 1, 4, 8, 12, 24 and 48 hour post dose; and on Days 8 and 30. Measurements were obtained after resting for at least 5 minutes in a supine position. Baseline was defined as the last scheduled non-missing measurement taken prior to drug administration. Change from Baseline was calculated as value at indicated time point minus Baseline value. Number of participants with worst change from Baseline in ECG have been presented as clinically significant (CS) change or not a clinically significant (NCS) change.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Curve (AUC) From Time Zero to Infinity [AUC (0-inf)], AUC From Time Zero to the Time of Last Quantifiable Concentration [AUC(0-t)], AUC From Time Zero to 24 Hours [AUC(0-24)] of GSK3389404 After Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate AUC (0-inf), AUC (0-t) and AUC (0-24) of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose. Pharmacokinetic Concentration Population was defined as participants who underwent plasma PK sampling and had evaluable PK assay results post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve (AUC) From Time Zero to Infinity [AUC (0-inf)], AUC From Time Zero to the Time of Last Quantifiable Concentration [AUC(0-t)], AUC From Time Zero to 24 Hours [AUC(0-24)] of GSK3389404 After Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate AUC (0-inf), AUC (0-t) and AUC (0-24) of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose. Pharmacokinetic Concentration Population was defined as participants who underwent plasma PK sampling and had evaluable PK assay results post-dose.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Nanogram*hour per milliliter(ng*hour/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632" spread="171.59"/>
                    <measurement group_id="O2" value="2080" spread="801.85"/>
                    <measurement group_id="O3" value="4750" spread="1450.8"/>
                    <measurement group_id="O4" value="8150" spread="3204.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" spread="80.962"/>
                    <measurement group_id="O2" value="1770" spread="961.03"/>
                    <measurement group_id="O3" value="3710" spread="1485.6"/>
                    <measurement group_id="O4" value="7440" spread="2844.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="592" spread="105.91"/>
                    <measurement group_id="O2" value="1970" spread="855.08"/>
                    <measurement group_id="O3" value="4330" spread="1313.5"/>
                    <measurement group_id="O4" value="7950" spread="3264.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax), Observed Concentration at 24 Hours (C24) and at 168 Hours (C168) of GSK3389404 Following Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate Cmax, C24 and C168 of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax), Observed Concentration at 24 Hours (C24) and at 168 Hours (C168) of GSK3389404 Following Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate Cmax, C24 and C168 of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="23.622"/>
                    <measurement group_id="O2" value="350" spread="257.48"/>
                    <measurement group_id="O3" value="584" spread="366.96"/>
                    <measurement group_id="O4" value="889" spread="496.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.0000"/>
                    <measurement group_id="O2" value="0.00" spread="0.0000"/>
                    <measurement group_id="O3" value="3.33" spread="8.1650"/>
                    <measurement group_id="O4" value="18.7" spread="17.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.0000"/>
                    <measurement group_id="O2" value="0.00" spread="0.0000"/>
                    <measurement group_id="O3" value="0.00" spread="0.0000"/>
                    <measurement group_id="O4" value="0.00" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax), Terminal Half-life (T1/2) and Lag Time (Tlag) of GSK3389404 Following Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax), Terminal Half-life (T1/2) and Lag Time (Tlag) of GSK3389404 Following Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.20"/>
                    <measurement group_id="O2" value="1.74" spread="0.48"/>
                    <measurement group_id="O3" value="2.67" spread="1.37"/>
                    <measurement group_id="O4" value="3.83" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="3.3937"/>
                    <measurement group_id="O2" value="4.67" spread="3.5530"/>
                    <measurement group_id="O3" value="6.07" spread="3.9531"/>
                    <measurement group_id="O4" value="4.27" spread="1.2281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tlag</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent SC Plasma Clearance (CL/F) of GSK3389404 Following Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate CL/F of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent SC Plasma Clearance (CL/F) of GSK3389404 Following Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate CL/F of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="4.2805"/>
                    <measurement group_id="O2" value="15.8" spread="4.6710"/>
                    <measurement group_id="O3" value="13.6" spread="3.6934"/>
                    <measurement group_id="O4" value="16.2" spread="4.7050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t), AUC(0-24), AUC From Time Zero to 168 Hours Post-dose [AUC(0-168)] and AUC (0-inf) of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate AUC (0-t), AUC (0-24), AUC (0-168) and AUC (0-inf) of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t), AUC(0-24), AUC From Time Zero to 168 Hours Post-dose [AUC(0-168)] and AUC (0-inf) of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate AUC (0-t), AUC (0-24), AUC (0-168) and AUC (0-inf) of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>ng*hour/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-t), n=6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1300" spread="286.51"/>
                    <measurement group_id="O2" value="4150" spread="1103.1"/>
                    <measurement group_id="O3" value="7970" spread="3082.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-24), n=6, 5, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1410" spread="292.51"/>
                    <measurement group_id="O2" value="4940" spread="1131.6"/>
                    <measurement group_id="O3" value="8330" spread="3363.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-168), n=6, 5, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420" spread="291.72"/>
                    <measurement group_id="O2" value="5080" spread="1332.6"/>
                    <measurement group_id="O3" value="8480" spread="3249.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf), n=6, 5, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420" spread="291.72"/>
                    <measurement group_id="O2" value="5080" spread="1328.9"/>
                    <measurement group_id="O3" value="8480" spread="3249.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax, C24 and C168 of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate Cmax, C24 and C168 of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax, C24 and C168 of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate Cmax, C24 and C168 of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236" spread="64.551"/>
                    <measurement group_id="O2" value="723" spread="216.01"/>
                    <measurement group_id="O3" value="1280" spread="633.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.0000"/>
                    <measurement group_id="O2" value="2.58" spread="6.3278"/>
                    <measurement group_id="O3" value="16.7" spread="20.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.0000"/>
                    <measurement group_id="O2" value="0.00" spread="0.0000"/>
                    <measurement group_id="O3" value="0.00" spread="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax, T1/2 and Tlag of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax, T1/2 and Tlag of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax, n=6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.03"/>
                    <measurement group_id="O2" value="2.01" spread="0.02"/>
                    <measurement group_id="O3" value="2.42" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2, n=6, 5, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="1.0621"/>
                    <measurement group_id="O2" value="3.47" spread="1.8907"/>
                    <measurement group_id="O3" value="4.04" spread="1.7867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tlag, n=6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate CL/F of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose. Only those participants with data available at the specified time points were analyzed.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate CL/F of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose. Only those participants with data available at the specified time points were analyzed.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="5.9872"/>
                    <measurement group_id="O2" value="12.5" spread="3.4120"/>
                    <measurement group_id="O3" value="15.6" spread="4.7861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24) and AUC From Time Zero to the End of the Dosing Interval [AUC(0-tau)] of GSK3389404 Following Dosing on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate AUC (0-24) and AUC (0-tau) of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days ).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) and AUC From Time Zero to the End of the Dosing Interval [AUC(0-tau)] of GSK3389404 Following Dosing on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate AUC (0-24) and AUC (0-tau) of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days ).</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>ng*hour/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1486" spread="364.92"/>
                    <measurement group_id="O2" value="3973" spread="906.81"/>
                    <measurement group_id="O3" value="8918" spread="3447.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-tau)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1598" spread="565.02"/>
                    <measurement group_id="O2" value="4052" spread="873.65"/>
                    <measurement group_id="O3" value="9047" spread="3361.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Concentration at the End of the Dosing Interval (Ctau), C24 and Cmax of GSK3389404 Following Dosing on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate Ctau, C24 and Cmax of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days ).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Concentration at the End of the Dosing Interval (Ctau), C24 and Cmax of GSK3389404 Following Dosing on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate Ctau, C24 and Cmax of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days ).</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ctau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.000"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0000"/>
                    <measurement group_id="O2" value="4.767" spread="7.4115"/>
                    <measurement group_id="O3" value="15.60" spread="18.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.7" spread="39.657"/>
                    <measurement group_id="O2" value="614.8" spread="211.25"/>
                    <measurement group_id="O3" value="1257" spread="799.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax, T1/2 and Tlag of GSK3389404 Following Dosing on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax, T1/2 and Tlag of GSK3389404 Following Dosing on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.98"/>
                    <measurement group_id="O2" value="2.26" spread="0.88"/>
                    <measurement group_id="O3" value="2.67" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.768" spread="3.2072"/>
                    <measurement group_id="O2" value="3.450" spread="1.6049"/>
                    <measurement group_id="O3" value="3.585" spread="1.2332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tlag</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cl/F of GSK3389404 Following Dosing on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate Cl/F of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cl/F of GSK3389404 Following Dosing on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate Cl/F of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.50" spread="6.3906"/>
                    <measurement group_id="O2" value="15.48" spread="3.6973"/>
                    <measurement group_id="O3" value="14.39" spread="3.7029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Proportionality of GSK202007 for Dose Range 10 mg - 120 mg After Single Dose Administrations</title>
        <description>Results of dose proportionality assessment using power model and analysis of variance (ANOVA) following single dose administariton (Part 1 and Day 1 in Part 2) are presented. Slope estimates and 90% confidence interval are presented for combined data of Day 1 of Part 1 and 2.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose; Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose in Part 2.</time_frame>
        <population>Pharmacokinetic Concentration Population (combined for Part 1 and 2). Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3389404 10-120 mg</title>
            <description>Participants received a single dose of either 10 mg or 30 mg or 60 mg or 120 mg of GSK3389404 by subcutaneous injection on Day 1 of Part 1 or Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Proportionality of GSK202007 for Dose Range 10 mg - 120 mg After Single Dose Administrations</title>
          <description>Results of dose proportionality assessment using power model and analysis of variance (ANOVA) following single dose administariton (Part 1 and Day 1 in Part 2) are presented. Slope estimates and 90% confidence interval are presented for combined data of Day 1 of Part 1 and 2.</description>
          <population>Pharmacokinetic Concentration Population (combined for Part 1 and 2). Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-24), n=40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.98" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf), n=40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.97" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, n=41</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.83" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Proportionality of GSK202007 for Dose Range 30 mg - 120 mg After Multiple Dose Administrations</title>
        <description>Results of proportionality assessment using power model and ANOVA following multiple doses are presented. Slope estimates and 90% confidence interval are presented for Day 22 of Part 2.</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115) in Part 2</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK3389404 30-120 mg</title>
            <description>Participants received a single dose of either 30 mg or 60 mg or 120 mg of GSK3389404 by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Proportionality of GSK202007 for Dose Range 30 mg - 120 mg After Multiple Dose Administrations</title>
          <description>Results of proportionality assessment using power model and ANOVA following multiple doses are presented. Slope estimates and 90% confidence interval are presented for Day 22 of Part 2.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-tau)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.04" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.96" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio by AUC (RAUC), by Cmax (RCmax), by C24 (RC24) and by Ctau (RCtau) of GSK3389404 in Part 2</title>
        <description>For Part 2, the extent of accumulation of GSK3389404 was evaluated by comparing AUC (0-tau), Cmax, C24 and Ctau on Day 22 to AUC (0-168), Cmax, C24 and C168 on Day 1. For each dose level, a linear mixed effect model was fitted with the log transformed PK parameter as the dependent variable, day as a fixed effect and subject as a random effect.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose; Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio by AUC (RAUC), by Cmax (RCmax), by C24 (RC24) and by Ctau (RCtau) of GSK3389404 in Part 2</title>
          <description>For Part 2, the extent of accumulation of GSK3389404 was evaluated by comparing AUC (0-tau), Cmax, C24 and Ctau on Day 22 to AUC (0-168), Cmax, C24 and C168 on Day 1. For each dose level, a linear mixed effect model was fitted with the log transformed PK parameter as the dependent variable, day as a fixed effect and subject as a random effect.</description>
          <population>Pharmacokinetic Concentration Population. Only data available at the specified time points was analyzed. (represented by n=X in the category titles).</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RAUC, n=6, 5, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.115" spread="0.24879"/>
                    <measurement group_id="O2" value="0.8596" spread="0.099034"/>
                    <measurement group_id="O3" value="1.094" spread="0.24035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RCmax, n=6, 6, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8683" spread="0.16676"/>
                    <measurement group_id="O2" value="0.8518" spread="0.18537"/>
                    <measurement group_id="O3" value="0.9920" spread="0.32054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RC24, n=0, 1, 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.8580" spread="NA">Only one participant was analyzed at this endpoint, hence standard deviation could not be calculated.</measurement>
                    <measurement group_id="O3" value="0.5890" spread="0.51139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RCtau, n=0, 0, 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Invariance (LI) of GSK3389404 in Part 2</title>
        <description>For Part 2, time invariance was evaluated by comparing AUC (0-tau) for Day 22 to AUC (0-inf) for Day 1. For each dose level, a linear mixed effect model was fitted with the log transformed PK parameter as the dependent variable, day as a fixed effect and subject as a random effect. Only those participants with data available at the specified time points were analyzed.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose; Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Invariance (LI) of GSK3389404 in Part 2</title>
          <description>For Part 2, time invariance was evaluated by comparing AUC (0-tau) for Day 22 to AUC (0-inf) for Day 1. For each dose level, a linear mixed effect model was fitted with the log transformed PK parameter as the dependent variable, day as a fixed effect and subject as a random effect. Only those participants with data available at the specified time points were analyzed.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.115" spread="0.24879"/>
                    <measurement group_id="O2" value="0.8598" spread="0.098644"/>
                    <measurement group_id="O3" value="1.094" spread="0.24035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentrations of GSK3389404 in Part 2</title>
        <description>For Part 2, mean plasma GSK3389404 pre-dose values between Day 1 to Day 29 and Ctau were plotted against time to assess attainment of GSK3389404 steady state following multiple dose administration. Achievement of plasma GSK3389404 steady-state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of log (Ctau) versus time. NA indicates data was not available.</description>
        <time_frame>Pre-dose on Days 8, 15, 22 and 29</time_frame>
        <population>Pharmacokinetic Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentrations of GSK3389404 in Part 2</title>
          <description>For Part 2, mean plasma GSK3389404 pre-dose values between Day 1 to Day 29 and Ctau were plotted against time to assess attainment of GSK3389404 steady state following multiple dose administration. Achievement of plasma GSK3389404 steady-state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of log (Ctau) versus time. NA indicates data was not available.</description>
          <population>Pharmacokinetic Concentration Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Trough plasma concentrations were below limit of quantification, hence data was not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-inf), AUC(0-t), AUC(0-24) of the Metabolite of GSK3389404 After Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate AUC (0-inf), AUC (0-t) and AUC (0-24) of metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-inf), AUC(0-t), AUC(0-24) of the Metabolite of GSK3389404 After Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate AUC (0-inf), AUC (0-t) and AUC (0-24) of metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-inf)</title>
            </class>
            <class>
              <title>AUC (0-t)</title>
            </class>
            <class>
              <title>AUC (0-24)</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate Cmax, C24 and C168 of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate Cmax, C24 and C168 of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
            </class>
            <class>
              <title>C24</title>
            </class>
            <class>
              <title>C168</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose in Part 1</title>
        <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: GSK3389404 10 mg</title>
            <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose in Part 1</title>
          <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 30 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
            </class>
            <class>
              <title>T1/2</title>
            </class>
            <class>
              <title>Tlag</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-t), AUC(0-24), AUC(0-168) and AUC (0-inf) of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate AUC (0-t), AUC (0-24), AUC (0-168) and AUC (0-inf) of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t), AUC(0-24), AUC(0-168) and AUC (0-inf) of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate AUC (0-t), AUC (0-24), AUC (0-168) and AUC (0-inf) of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-t)</title>
            </class>
            <class>
              <title>AUC (0-24)</title>
            </class>
            <class>
              <title>AUC (0-168)</title>
            </class>
            <class>
              <title>AUC (0-inf)</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate Cmax, C24 and C168 of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate Cmax, C24 and C168 of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
            </class>
            <class>
              <title>C24</title>
            </class>
            <class>
              <title>C168</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
        <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
        <time_frame>Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2</title>
          <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 1 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 8 and 15 post-dose.</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
            </class>
            <class>
              <title>T1/2</title>
            </class>
            <class>
              <title>Tlag</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24) and AUC(0-tau) of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate AUC (0-24) and AUC (0-tau) of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) and AUC(0-tau) of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate AUC (0-24) and AUC (0-tau) of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-24)</title>
            </class>
            <class>
              <title>AUC (0-tau)</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctau, C24 and Cmax of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate Ctau, C24 and Cmax of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctau, C24 and Cmax of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate Ctau, C24 and Cmax of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ctau</title>
            </class>
            <class>
              <title>C24</title>
            </class>
            <class>
              <title>Cmax</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Dosing on Day 22 of Part 2</title>
        <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
        <time_frame>Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 115)</time_frame>
        <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: GSK3389404 30 mg</title>
            <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: GSK3389404 60 mg</title>
            <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: GSK3389404 120 mg</title>
            <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Dosing on Day 22 of Part 2</title>
          <description>Blood samples were collected to evaluate Tmax, T1/2 and Tlag of the metabolite of GSK3389404 on Day 22 (pre-dose) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose; and on Days 29, 36, 50, 71 and at Follow-up (Day 113+- 2 days).</description>
          <population>Pharmacokinetic Concentration Population. Based on emerging PK results during the course of the study, it was observed that metabolite plasma concentrations were not quantifiable in any PK sample. Hence, PK parameters could not be estimated for metabolite.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
            </class>
            <class>
              <title>T1/2</title>
            </class>
            <class>
              <title>Tlag</title>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of the study treatment up to 62 days in Part 1 and up to 115 days in Part 2.</time_frame>
      <desc>On treatment SAEs and non-serious AEs were reported for the Safety Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Placebo</title>
          <description>Participant received a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: GSK3389404 10 mg</title>
          <description>Participants received a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: GSK3389404 30 mg</title>
          <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: GSK3389404 60 mg</title>
          <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: GSK3389404 120 mg</title>
          <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 2: Placebo</title>
          <description>Participant received a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: GSK3389404 30 mg</title>
          <description>Participants received a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="E8">
          <title>Part 2: GSK3389404 60 mg</title>
          <description>Participants received a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
        <group group_id="E9">
          <title>Part 2: GSK3389404 120 mg</title>
          <description>Participants received a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

